Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 26, 2025 03:00 ET | Source: Pleco Therapeutics B.V.

Pleco Therapeutics Announces Positive Outcome of Pre-IND meeting with FDA for PTX-252 in Acute Myeloid Leukaemia

Pleco Therapeutics announces positive FDA feedback on PTX-252, supporting IND pathway for its novel AML treatment.
January 16, 2024 11:30 ET | Source: Pleco Therapeutics B.V.

Pleco Therapeutics receives FDA Orphan Drug Designation

The U.S Food and Drug Administration (FDA) has granted Orphan Drug Designation to Pleco Therapeutics BV’s lead compound, PTX-252 for the treatment of AML.